Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026)
Savara (SVRA) reported Net Income towards Common Stockholders of -$37.3 million for Q1 2026, down 39.96% year-over-year from -$62.1 million in Q1 2025, and down 15.66% on a QoQ basis from -$32.2 million in Q4 2025.
Savara (SVRA) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$37.3 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 39.96% year-over-year to -$37.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129.5 million (down 26.73% YoY) and the FY2025 annual result came in at -$118.8 million, down 23.94% from the prior year.
- Net Income towards Common Stockholders declined to -$37.3 million in Q1 2026 per SVRA's latest filing, from -$32.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$8.3 million in Q1 2022 and bottomed at -$37.3 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is -$20.3 million (2024), against an average of -$20.3 million.
- The widest annual swing landed in 2022, when Net Income towards Common Stockholders rose 18.76%; it then tumbled 94.38% in 2024.
- Tracing SVRA's Net Income towards Common Stockholders over 5 years: stood at -$10.3 million in 2022, then plunged by 56.3% to -$16.1 million in 2023, then tumbled by 80.41% to -$29.0 million in 2024, then fell by 10.99% to -$32.2 million in 2025, then declined by 15.66% to -$37.3 million in 2026.
- Per Business Quant, the three latest SVRA Net Income towards Common Stockholders figures stand at -$37.3 million (Q1 2026), -$32.2 million (Q4 2025), and -$29.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | -37.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.28 Mn |
| Dec 31, 2025 | -32.24 Mn |
| Sep 30, 2025 | -29.56 Mn |
| Jun 30, 2025 | -30.40 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.04 Mn |
| Sep 30, 2024 | -24.25 Mn |
| Jun 30, 2024 | -22.24 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.10 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -11.44 Mn |
| Mar 31, 2023 | -10.56 Mn |
| Dec 31, 2022 | -10.30 Mn |
| Sep 30, 2022 | -10.39 Mn |
| Jun 30, 2022 | -9.16 Mn |
| Mar 31, 2022 | -8.30 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -10.55 Mn |
| Jun 30, 2021 | -10.94 Mn |
| Mar 31, 2021 | -10.22 Mn |
| Dec 31, 2020 | -13.74 Mn |
| Sep 30, 2020 | -11.06 Mn |
| Jun 30, 2020 | -9.39 Mn |
| Mar 31, 2020 | -15.42 Mn |
| Dec 31, 2019 | -31.72 Mn |
| Sep 30, 2019 | -12.40 Mn |
| Jun 30, 2019 | -21.94 Mn |
| Mar 31, 2019 | -12.11 Mn |
| Dec 31, 2018 | -10.51 Mn |
| Sep 30, 2018 | -12.56 Mn |
| Jun 30, 2018 | -11.59 Mn |
| Mar 31, 2018 | -26.85 Mn |
| Dec 31, 2017 | -6.50 Mn |
| Sep 30, 2017 | -6.82 Mn |
| Jun 30, 2017 | -12.46 Mn |
| Mar 31, 2017 | -5.00 Mn |
| Dec 31, 2016 | -6.04 Mn |
| Sep 30, 2016 | -3.27 Mn |
| Jun 30, 2016 | -2.05 Mn |
| Mar 31, 2016 | -11.21 Mn |
| Dec 31, 2015 | -10.16 Mn |
| Sep 30, 2015 | -9.91 Mn |
| Jun 30, 2015 | -10.15 Mn |
| Mar 31, 2015 | -9.62 Mn |
| Dec 31, 2014 | -7.31 Mn |
| Sep 30, 2014 | -7.87 Mn |
| Jun 30, 2014 | -7.15 Mn |
| Mar 31, 2014 | -6.37 Mn |
| Dec 31, 2013 | -5.71 Mn |
| Sep 30, 2013 | -5.25 Mn |
| Jun 30, 2013 | -4.94 Mn |
| Mar 31, 2013 | -5.58 Mn |
| Dec 31, 2012 | -4.00 Mn |
| Sep 30, 2012 | -3.20 Mn |
| Jun 30, 2012 | -4.21 Mn |
| Mar 31, 2012 | -4.15 Mn |
| Dec 31, 2011 | -2.37 Mn |
| Sep 30, 2011 | -3.54 Mn |
| Jun 30, 2011 | -4.39 Mn |
| Mar 31, 2011 | -2.96 Mn |
| Dec 31, 2010 | -2.28 Mn |
| Sep 30, 2010 | -1.84 Mn |
| Jun 30, 2010 | -5.04 Mn |